Insider Patrick Finn plans $3.56M Twist Bioscience (TWST) stock sale

Rhea-AI Filing Summary

Twist Bioscience insider Patrick Finn filed a notice of proposed sale of 68,967 shares of the company’s common stock under Rule 144. The shares have an aggregate market value of $3,562,414.66 and are to be sold through Fidelity Brokerage Services LLC on NASDAQ.

The filing notes that 61,311,704 shares of common stock were outstanding, providing context for the planned sale. It also lists how Finn acquired these securities over time, including option grants and exercises, restricted stock vesting, and employee stock purchase plan participation, as well as his common stock sales in the prior three months.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	68967	3562414.66	61311704	02/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/17/2026	Option Granted - 11/19/2018	Issuer			32300	02/17/2026	Cash
Common	02/17/2026	Option Granted - 10/24/2019	Issuer			18205	02/17/2026	Cash
Common	05/26/2020	Option Exercised	Issuer			1684	05/26/2020	Cash
Common	05/20/2022	Restricted Stock Vesting	Issuer			923	05/20/2022	Compensation
Common	07/01/2022	Restricted Stock Vesting	Issuer			408	07/01/2022	Compensation
Common	08/20/2022	Restricted Stock Vesting	Issuer			923	08/20/2022	Compensation
Common	10/01/2022	Restricted Stock Vesting	Issuer			408	10/01/2022	Compensation
Common	01/01/2024	Restricted Stock Vesting	Issuer			484	01/01/2024	Compensation
Common	01/22/2024	Restricted Stock Vesting	Issuer			199	01/22/2024	Compensation
Common	04/01/2024	Restricted Stock Vesting	Issuer			374	04/01/2024	Compensation
Common	08/02/2024	Restricted Stock Vesting	Issuer			2101	08/02/2024	Compensation
Common	08/20/2024	Employee Stock Purchase Plan	Issuer			282	08/20/2024	Cash
Common	11/02/2024	Restricted Stock Vesting	Issuer			2305	11/02/2024	Compensation
Common	11/05/2024	Restricted Stock Vesting	Issuer			3400	11/05/2024	Compensation
Common	02/20/2025	Employee Stock Purchase	Issuer			364	02/20/2025	Cash
Common	04/01/2025	Restricted Stock Vesting	Issuer			173	04/01/2025	Compensation
Common	04/22/2025	Restricted Stock Vesting	Issuer			2074	04/22/2025	Compensation
Common	02/02/2024	Restricted Stock Vesting	Issuer			2360	02/02/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	11/21/2025	1776	47070.22
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	01/13/2026	23279	931160.00
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	01/23/2026	2390	107329.41
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	02/03/2026	2705	125986.73
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	02/12/2026	3500	175789.05
Patrick Finn 681 Gateway Blvd South San Francisco CA 94080	Common	02/13/2026	1750	87572.01

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Twist Bioscience (TWST) insider Patrick Finn disclose in this Form 144?

Patrick Finn discloses a proposed sale of 68,967 Twist Bioscience common shares under Rule 144. The filing details share acquisition history, the chosen broker, exchange, and context such as total shares outstanding and recent stock sale activity over the past three months.

How many Twist Bioscience (TWST) shares does Patrick Finn plan to sell and what is their value?

The notice covers 68,967 shares of Twist Bioscience common stock with aggregate market value of $3,562,414.66. This amount reflects the market value at the time indicated and is tied specifically to the proposed Rule 144 sale described in the filing.

Which broker and exchange are used for Patrick Finn’s proposed Twist Bioscience (TWST) share sale?

The proposed sale is to be executed through Fidelity Brokerage Services LLC. The filing specifies that the 68,967 Twist Bioscience common shares are expected to be sold on the NASDAQ exchange, indicating use of a major U.S. electronic marketplace for the transaction.

How many Twist Bioscience (TWST) shares were outstanding when this Form 144 was prepared?

The filing reports 61,311,704 Twist Bioscience common shares outstanding. This figure provides a baseline to understand the relative size of Patrick Finn’s proposed 68,967-share sale in the broader context of the company’s total equity base at that time.

How did Patrick Finn acquire the Twist Bioscience (TWST) shares he plans to sell?

The filing shows Finn acquired shares through option grants dated 11/19/2018 and 10/24/2019, option exercises, multiple restricted stock vesting events, and employee stock purchase plan transactions. It also lists whether consideration was cash or compensation for each acquisition entry.

What recent Twist Bioscience (TWST) stock sales by Patrick Finn are disclosed in the Form 144?

The document lists several recent sales, including 1,776 shares on 11/21/2025 and 23,279 shares on 01/13/2026. Additional transactions include sales of 2,390, 2,705, 3,500, and 1,750 shares on various dates in early 2026 with corresponding gross proceeds figures.